KEY TAKEAWAYS
- The BIOPAC trial aimed to investigate the association between suPAR levels and OS in pts with advanced PDAC.
- Serum samples were collected and analyzed using TR-FIA. The Cox proportional hazards model assessed the association between suPAR levels and OS.
High levels of urokinase-type Plasminogen Activator Receptor (uPAR) in tissue and blood are linked to poor prognosis in several types of cancer but not in pancreatic ductal adenocarcinoma (PDAC).
Researchers aimed to investigate the association between soluble forms of uPAR (suPAR) levels and overall survival(OS) in pts with advanced pancreatic ductal adenocarcinoma (PDAC).
In the training cohort, a high suPAR domain I level emerged as an independent biomarker associated with shorter OS (HR, 1.37, 95% CI 1.15-1.63, P= 0.0004). Additionally, high CA19-9 levels (HR, 1.08, 95% CI 1.04-1.12, P< 0.0001), performance status (PS), and disease stage were also independent prognostic factors in this cohort. In the validation cohort, elevated suPAR domain I (HR, 1.91, 95% CI 1.36-2.69, P= 0.0002) and CA 19-9 levels (HR, 1.09, 95% CI 1.01-1.17, P= 0.02) were confirmed as independent prognostic biomarkers associated with shorter overall survival. No correlation was observed between suPAR domain I and CA19-9 levels (r = 0.059, P= 0.21).
The study found high suPAR domain 1 levels were associated with poor prognosis in PDAC pts, independent of CA19-9.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e16277
Clinical Trial: https://clinicaltrials.gov/study/NCT03311776
Rikke Løvendahl Eefsen, Ib Jarle Christensen, Dan Calatyud, Astrid Zedlitz Johansen, Inna Markovna Chen, Louise Skau Rasmussen, Per Pfeiffer, Niels Henrik Hollander, Fahimeh Andersen, Julia S. Johansen, and Gunilla Hoyer-Hansen. DOI:10.1200/JCO.2023.41.16_suppl.e16277 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e16277-e16277.
